ACTH (1-34) — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

ACTH (1-34)

Also known as: Adrenocorticotropin (1-34), Adrenocorticotropic Hormone Fragment (1-34), ACTH1-34

Synthetic N-terminal fragment of adrenocorticotropic hormone (ACTH) / melanocortin receptor agonist / adrenal steroidogenesis stimulator

Research chemicalLast updated: October 31, 2026Based on 13 peer-reviewed studies

What it is

ACTH (1-34) is a synthetic fragment of the pituitary hormone ACTH that triggers the adrenal glands to release cortisol. It is not the same product as Cortrosyn: the FDA-approved adrenal stimulation test uses cosyntropin, which is ACTH (1-24). Prohibited in competitive sport by WADA.

The scientific side

ACTH(1-34) is the biologically active N-terminal 34-amino-acid fragment of the 39-amino-acid full-length adrenocorticotropic hormone (ACTH). Full biological activity of ACTH resides within the first 24 residues (ACTH 1-24 = cosyntropin/tetracosactide), while the C-terminal residues 25-39 contribute to immunogenic and pharmacokinetic properties. ACTH is itself derived from proopiomelanocortin (POMC), a precursor that also gives rise to α-MSH, β-endorphin, and related peptides. The primary mechanism is activation of the melanocortin-2 receptor (MC2R), the adrenal-specific GPCR expressed on adrenocortical zona fasciculata and zona reticularis cells (PMID 23392095, PMID 18713819). MC2R is a Gs-coupled receptor: binding elevates adenylyl cyclase activity, increases intracellular cAMP, and activates PKA, which phosphorylates StAR (steroidogenic acute regulatory protein) and upregulates transcription of steroidogenic enzymes including P450scc (CYP11A1), P450c17 (CYP17A1), 21-hydroxylase (CYP21A2), and 11β-hydroxylase (CYP11B1). This cascade drives de novo cortisol (and to a lesser extent aldosterone) biosynthesis from cholesterol in a dose-dependent manner. Beyond adrenal steroidogenesis, ACTH(1-24) has been shown to stimulate non-insulin-mediated glucose uptake (NIMGU) in skeletal muscle cells via a carrier-mediated mechanism at physiological to supraphysiological concentrations. ACTH binds melanocortin receptors expressed on melanocytes, contributing to melanogenic activity — ACTH(1-24) is a moderate potency melanogenesis stimulator compared to α-MSH. MC2R function requires the accessory protein MRAP (MC2R Accessory Protein) for proper receptor trafficking to the cell membrane. Genetic defects in MC2R, MRAP, or StAR cause familial glucocorticoid deficiency (ACTH resistance syndrome), demonstrating the essentiality of this signaling cascade. Repository corticotropin (full-length ACTH 1-39) and synthetic ACTH(1-24) depot formulations produce different steroidogenic exposure profiles — ACTH(1-24) depot provides substantially higher peak cortisol stimulation than repository corticotropin at therapeutic doses. In clinical diagnostics, the standard 250-µg cosyntropin stimulation test (CST) is the gold standard for adrenal insufficiency diagnosis; post-ACTH cortisol ≥18-18.1 µg/dL at 30–60 minutes indicates intact adrenal reserve (PMID 33122342, PMID 42139516).

Class: Synthetic N-terminal fragment of adrenocorticotropic hormone (ACTH) / melanocortin receptor agonist / adrenal steroidogenesis stimulator

Administration & storage

Administration
Intravenous injection — standard diagnostic cosyntropin stimulation test (PMID: 33122342)Intravenous injection — low-dose 1 µg protocol (PMID: 24485487)Intramuscular injection — depot tetracosactide 5 µg/kg in animal studies (PMID: 26507252)
Storage
No specific storage data from reviewed abstracts. Standard pharmaceutical guidance: lyophilized powder stored as per the supplier's labeling; reconstituted solution should be used immediately or refrigerated and used within manufacturer-specified timeframe.
Cautions
No adverse reactions were observed in a feline clinical study of synthetic ACTH across 1–125 µg/kg doses. Standard cosyntropin is well-tolerated in clinical diagnostics.,ACTH stimulation may precipitate adrenal crisis in patients with severely depleted adrenal function — appropriate monitoring and resuscitation availability recommended for clinical testing.,Repository corticotropin (full-length ACTH 1-39) produces substantially lower steroidogenic exposure than synthetic ACTH(1-24) depot at equivalent labeled doses — these formulations are pharmacologically non-equivalent and dose-selection must account for this.,ACTH is WADA-prohibited; competitive athletes must not use ACTH or its fragments for non-therapeutic purposes.

Legal & regulatory status

US FDA

ACTH (1-34) is not itself an FDA-approved product. The FDA-approved diagnostic for adrenocortical function is cosyntropin (Cortrosyn), which is ACTH (1-24), a different peptide. Not approved for therapeutic adrenal…

WADA

ACTH and its fragments are listed under S2 Peptide Hormones on the WADA Prohibited List due to their corticosteroid-stimulating activity. Use in competition is prohibited. Athletes should verify current rules with their…

Health Canada

Not stated in reviewed literature — requires manual verification. Tetracosactide (Synacthen) is ACTH (1-24), a different peptide from ACTH (1-34).